PCSK9 inhibitor - Aanastra
Latest Information Update: 17 May 2024
At a glance
- Originator Aanastra
- Class Antihyperlipidaemics; Peptides; RNA
- Mechanism of Action PCSK9 protein expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hyperlipoproteinaemia type II